{"slug":"venetoclax","tag":"venetoclax","variants":["venetoclax"],"description":"No description yet","count":5,"kinds":{"person":5},"related":[{"slug":"cll","tag":"cll","shared":3},{"slug":"aml","tag":"aml","shared":2},{"slug":"australia","tag":"australia","shared":2},{"slug":"fixed-duration","tag":"fixed-duration","shared":1},{"slug":"guidelines","tag":"guidelines","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","tldr":"Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia."},{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","route":"/people/andrew-wei/","tldr":"Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML."},{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","route":"/people/kirsten-fischer/","tldr":"Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment."},{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","route":"/people/barbara-eichhorst/","tldr":"Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients."},{"id":"john-seymour","kind":"person","name":"John F. Seymour","route":"/people/john-seymour/","tldr":"Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL."}]}